Efficacy and Safety of Umbralisib and Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) By admin / 12/12/2021
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL. By admin / 06/20/2015
